The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial.
Akiko Hisamoto
No relevant relationships to disclose
Jiichiro Sasaki
No relevant relationships to disclose
Nagio Takigawa
Honoraria - AstraZeneca; Sanofi
Yoshiyuki Shioyama
No relevant relationships to disclose
Junji Kishimoto
No relevant relationships to disclose
Mitsuhiro Takemoto
No relevant relationships to disclose
Katsuyuki Hotta
Honoraria - AstraZeneca; Nippon Kayaku; Sanofi
Mitsune Tanimoto
No relevant relationships to disclose
Yukito Ichinose
No relevant relationships to disclose
Katsuyuki Kiura
Honoraria - AstraZeneca; Nippon Kayaku; Sanofi